- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02355990
Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study
November 27, 2022 updated by: Sanoculis Ltd
The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tel Hashomer, Israel
- Goldschleger Eye Institute, The Chaim Sheba Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- End Stage primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma in the study eye (EGS criteria)
- Optic nerve appearance characteristic of glaucoma in the study eye
- Best-corrected visual acuity (BCVA) of counting-fingers, hand movements, light perception or no light perception due to glaucomatous loss of central vision in the study eye
- Patient is treated with 1 to 5 hypotensive medications in the study eye
- Unsatisfactory medicated IOP (≥ 18 mmHg) at the screening visit in the study eye
- Shaffer grade ≥ III in all four angle quadrants in the study eye
- Subject is able and willing to attend all scheduled follow-up exams
- Subject understands and signs the informed consent
Exclusion Criteria:
Subjects presenting 1 or more of the following criteria will not be enrolled in the trial:
- Ocular conditions with a poorer prognosis in the fellow eye than in the study eye
- Closed angle forms of glaucoma in either eye
- Congenital or developmental glaucoma in either eye
- Other secondary glaucoma (such as neovascular, uveitic, lens-induced, trauma-induced, or glaucoma associated with increased episcleral venous pressure) in the study eye
- Peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities in the study eye
- Subject has history of penetrating keratoplasty (PKP)
- Any previous surgery in the study eye (except for clear corneal cataract surgery) where the conjunctiva is not intact and elastic.
- Any ocular disease or history in study eye such as severe dry eye, active proliferative retinopathy, ICE syndrome, epithelial or fibrous down growth, and ocular pathology that may interfere with accurate IOP measurements
- Prior surgery for an ab-interno or ab-externo device implanted in or through the Schlemm's canal in the study eye.
- Use of oral hypotensive medication for glaucoma for treatment of the fellow eye
- Less than the minimum visual function required for driving in the fellow eye: best-corrected visual acuity worse than 20/40 (Snellen equivalent) or Esterman visual field score less than 85%.
- History of idiopathic or autoimmune uveitis in either eye
- Severe trauma in study eye
- active iris neovascularization, previous cyclodestructive procedure, prior scleral buckling procedure, presence of silicone oil, need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery in study eye within 12 month period
- Vitreous present in anterior chamber, prior vitrectomy or virteous hemorrhage in study eye
- Aphakia
- Prior vitreoretinal surgery in study eye
- Clinically significant ocular inflammation or infection within 90 days prior to screening
- Unable to discontinue use of blood thinners in accordance with surgeon's standard preoperative instructions
- Uncontrolled systemic disease that in the opinion of the investigator would put the subject's health at risk and/or prevent the subject from completing all study visits
- Current participation or participation in another investigational drug or device clinical trial within the last 30 days before screening visit
- Pregnant or lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MIMS
Minimally Invasive Micro Sclerostomy
|
Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall incidence of serious adverse events
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of serious adverse events
Time Frame: 24 weeks
|
24 weeks
|
intraocular pressure (IOP) between 6 mmHg and 15 mmHg without medication
Time Frame: 24 weeks
|
24 weeks
|
Change in number of glaucoma medications from baseline in the study eye
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Daniel Cotlear, MD
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2015
Primary Completion (Actual)
January 1, 2019
Study Completion (Actual)
December 15, 2020
Study Registration Dates
First Submitted
January 31, 2015
First Submitted That Met QC Criteria
February 3, 2015
First Posted (Estimate)
February 4, 2015
Study Record Updates
Last Update Posted (Actual)
November 30, 2022
Last Update Submitted That Met QC Criteria
November 27, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAN-FIM-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open Angle Glaucoma
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Glaucot Teknoloji Anonim SirketiRecruitingPrimary Open-Angle GlaucomaTurkey
-
China Medical University HospitalCompletedEffect of Acupuncture on Visual Acuity and Visual Field in Patients With Primary Open-angle GlaucomaPrimary Open-angle GlaucomaTaiwan
-
InnFocus Inc.CompletedPrimary Open-angle GlaucomaSpain, United States, United Kingdom, France, Italy
-
Glaukos CorporationTerminatedPrimary Open-Angle GlaucomaUnited States
-
Rehab mahmoud abdelhamid mohamedCairo UniversityCompletedPrimary Open-angle GlaucomaEgypt
-
Cairo UniversityUniversity of LuebeckUnknown
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
Qlaris Bio, Inc.RecruitingPrimary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)United States
-
Peking UniversityRecruitingPrimary Open Angle Glaucoma | Ocular Hypertension | Primary Open Angle Glaucoma of Both Eyes | Primary Open-Angle Glaucoma, Unspecified Eye | Suspect GlaucomaChina
Clinical Trials on Minimally Invasive Micro Sclerostomy
-
Sanoculis LtdCompleted
-
Sanoculis LtdCompleted
-
Sanoculis LtdNot yet recruitingPrimary Open Angle Glaucoma | Open Angle Glaucoma
-
Fondazione Poliambulanza Istituto OspedalieroAssistance Publique - Hôpitaux de Paris; King's College Hospital NHS Trust; Fondazione... and other collaboratorsRecruitingNeoplasm Metastasis | Colorectal Neoplasms MalignantItaly, Belgium, France, Germany, Luxembourg, Netherlands, Norway, Russian Federation, Spain, United Kingdom
-
Radboud University Medical CenterDutch Heart Foundation; Penumbra Inc.CompletedIntracerebral Hemorrhage | Surgical Procedures, Minimally InvasiveNetherlands
-
Postgraduate Institute of Dental Sciences RohtakCompleted
-
Osama Mohammad Ali ElDamshetyUnknown
-
University of FloridaCompletedStroke | Atrial FibrillationUnited States
-
Istituto Clinico HumanitasFondazione Umberto VeronesiRecruiting
-
East China University of Science and TechnologyShanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to... and other collaboratorsCompleted